T GFR improvements on telbivudine treatment for up to 6 years compared with GFR declines on lamivudine therapy. Improvement was greatest in patients more than 50 years old and those with abnormal MedChemExpress 78919-13-8 baseline GFR; and was not associated with baseline ascites, virologic response or reduction in Child-Pugh score [27]. GFR improvement on telbivudine stands in contrast to the declines over time observed in studies of tenofovir [28] and entecavir [29]. Interestingly, GFR modeling data from Mauss et al. predict a year-on-year GFR reduction ofapproximately 2 mL/min in untreated HBV monoinfection which is halved, but not abolished, by monotherapy with lamivudine, adefovir, entecavir or tenofovir [30]. Telbivudine was not studied in the Mauss model, and more research is needed to confirm and provide a SPDP Crosslinker web mechanism for the apparent dissimilarity of telbivudine to the other nucleosides with respect to GFR preservation. The Roadmap algorithm does not consider baseline HBV DNA in treatment decisions [16]. However, in this study, high baseline DNA was predictive of detectable Week 24 viremia requiring intensification. Almost three-quarters of patients who received tenofovir had baseline HBV DNA 9 log10 copies/mL. In future, baseline viremia may need to be considered in any treatment algorithm where decisions are made on the presence of detectable viremia early on therapy. In conclusion, telbivudine with conditional tenofovir intensification according to the Roadmap algorithm was well tolerated and, over 52 weeks, resulted in very high rates of undetectable HBV DNA, ALT normalization, and HBeAg/HBsAg clearance and seroconversion in nucleoside-naive HBeAg+ patients with chronic HBV infection, along with an improvement in GFR. The Roadmap appears to be a highly effective approach to HBV treatment and 104-week data from this study are awaited.Supporting InformationTable S1 List of ethics committees/institutional review boards.(PDF)Checklist S1 CONSORT checklist.(DOCX)Protocol S1 Study protocol.(PDF)Telbivudine 6 Conditional Tenofovir: 52-Week DataAuthor ContributionsCritical manuscript review and amendment: TP PK TT WS HLYC MGP EF SKO FB JD SZ HC RP YD AT. Conceived and designed theexperiments: TP RP YD AT. Performed the experiments: TP PK TT WS HLYC MGP EF SKO FB JD SZ HC. Analyzed the data: TP RP 
YD AT. Wrote the paper: YD.
Systemic lupus erythematosus (SLE) is a chronic inflammatory and autoimmune disease. The Lupus Foundation of America estimates that 1.5 million Americans have lupus and at least 5 million worldwide. The average annual direct health care cost per patient with SLE was 12,643 in the USA as reported in 2008, which imposes a considerable financial burden on the nation and the patient’s family [1]. SLE can affect almost all parts of the body. Among them, renal involvement (lupus nephritis) is the foremost cause of morbidity and mortality in SLE patients [2]. Lupus nephritis is characterized by repeated episodes of flares. To 
date, renal biopsy remains the gold standard to diagnose and assess the disease status of lupus nephritis patients. However, due to inherent limitations of potential sampling errors and its invasive nature, multiple biopsies that are necessary for the assessment of the disease or treatment efficacy are undesirable and not routinely clinically performed. Moreover, clinically silent chronic changes of glomerulosclerosis and interstitial fibrosis secondary to chronic inflammation may go undetected with biopsy. These changes pr.T GFR improvements on telbivudine treatment for up to 6 years compared with GFR declines on lamivudine therapy. Improvement was greatest in patients more than 50 years old and those with abnormal baseline GFR; and was not associated with baseline ascites, virologic response or reduction in Child-Pugh score [27]. GFR improvement on telbivudine stands in contrast to the declines over time observed in studies of tenofovir [28] and entecavir [29]. Interestingly, GFR modeling data from Mauss et al. predict a year-on-year GFR reduction ofapproximately 2 mL/min in untreated HBV monoinfection which is halved, but not abolished, by monotherapy with lamivudine, adefovir, entecavir or tenofovir [30]. Telbivudine was not studied in the Mauss model, and more research is needed to confirm and provide a mechanism for the apparent dissimilarity of telbivudine to the other nucleosides with respect to GFR preservation. The Roadmap algorithm does not consider baseline HBV DNA in treatment decisions [16]. However, in this study, high baseline DNA was predictive of detectable Week 24 viremia requiring intensification. Almost three-quarters of patients who received tenofovir had baseline HBV DNA 9 log10 copies/mL. In future, baseline viremia may need to be considered in any treatment algorithm where decisions are made on the presence of detectable viremia early on therapy. In conclusion, telbivudine with conditional tenofovir intensification according to the Roadmap algorithm was well tolerated and, over 52 weeks, resulted in very high rates of undetectable HBV DNA, ALT normalization, and HBeAg/HBsAg clearance and seroconversion in nucleoside-naive HBeAg+ patients with chronic HBV infection, along with an improvement in GFR. The Roadmap appears to be a highly effective approach to HBV treatment and 104-week data from this study are awaited.Supporting InformationTable S1 List of ethics committees/institutional review boards.(PDF)Checklist S1 CONSORT checklist.(DOCX)Protocol S1 Study protocol.(PDF)Telbivudine 6 Conditional Tenofovir: 52-Week DataAuthor ContributionsCritical manuscript review and amendment: TP PK TT WS HLYC MGP EF SKO FB JD SZ HC RP YD AT. Conceived and designed theexperiments: TP RP YD AT. Performed the experiments: TP PK TT WS HLYC MGP EF SKO FB JD SZ HC. Analyzed the data: TP RP YD AT. Wrote the paper: YD.
Systemic lupus erythematosus (SLE) is a chronic inflammatory and autoimmune disease. The Lupus Foundation of America estimates that 1.5 million Americans have lupus and at least 5 million worldwide. The average annual direct health care cost per patient with SLE was 12,643 in the USA as reported in 2008, which imposes a considerable financial burden on the nation and the patient’s family [1]. SLE can affect almost all parts of the body. Among them, renal involvement (lupus nephritis) is the foremost cause of morbidity and mortality in SLE patients [2]. Lupus nephritis is characterized by repeated episodes of flares. To date, renal biopsy remains the gold standard to diagnose and assess the disease status of lupus nephritis patients. However, due to inherent limitations of potential sampling errors and its invasive nature, multiple biopsies that are necessary for the assessment of the disease or treatment efficacy are undesirable and not routinely clinically performed. Moreover, clinically silent chronic changes of glomerulosclerosis and interstitial fibrosis secondary to chronic inflammation may go undetected with biopsy. These changes pr.